logo
Sign In
    Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
    ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
    Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
    Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
    Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
    For ProvidersRequest DemoJoin Research Panel
    For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
    Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
    CompanyAboutInsightsCareersContact
    Legit Script Certified
    Get the latest insights in your inbox
    Follow us
    Legit Script Certified
    • Terms and Conditions
    • Privacy Policy
    • © 2025 PrescriberPoint. All Rights Reserved.

    Drugs interactions for

    • 0 Major drug interactions
    • 1 Moderate drug interactions (including ingredients like Pozelimab)
    • 159 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
    160 interactions for
    A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and .
    Pozelimab
    The serum concentration of Pozelimab can be decreased when it is combined with Eptinezumab.
    Adalimumab
    The risk or severity of adverse effects can be increased when Adalimumab is combined with Eptinezumab.
    Aducanumab
    The risk or severity of adverse effects can be increased when Aducanumab is combined with Eptinezumab.
    Alemtuzumab
    The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eptinezumab.
    Alirocumab
    The risk or severity of adverse effects can be increased when Alirocumab is combined with Eptinezumab.
    Amivantamab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Amivantamab.
    Anifrolumab
    The risk or severity of adverse effects can be increased when Anifrolumab is combined with Eptinezumab.
    Ansuvimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Ansuvimab.
    Anthrax immune globulin human
    The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Eptinezumab.
    Antilymphocyte immunoglobulin (horse)
    The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Eptinezumab.
    Antithymocyte immunoglobulin (rabbit)
    The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eptinezumab.
    Asfotase alfa
    The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Eptinezumab.
    Atezolizumab
    The risk or severity of adverse effects can be increased when Atezolizumab is combined with Eptinezumab.
    Atoltivimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Atoltivimab.
    Avelumab
    The risk or severity of adverse effects can be increased when Avelumab is combined with Eptinezumab.
    Axatilimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Axatilimab.
    Bamlanivimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Bamlanivimab.
    Basiliximab
    The risk or severity of adverse effects can be increased when Basiliximab is combined with Eptinezumab.
    Belimumab
    The risk or severity of adverse effects can be increased when Belimumab is combined with Eptinezumab.
    Benralizumab
    The risk or severity of adverse effects can be increased when Benralizumab is combined with Eptinezumab.
    Bevacizumab
    The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.
    Bezlotoxumab
    The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Eptinezumab.
    Bimekizumab
    The risk or severity of adverse effects can be increased when Bimekizumab is combined with Eptinezumab.
    Blinatumomab
    The risk or severity of adverse effects can be increased when Blinatumomab is combined with Eptinezumab.
    Brentuximab vedotin
    The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eptinezumab.
    Brodalumab
    The risk or severity of adverse effects can be increased when Brodalumab is combined with Eptinezumab.
    Brolucizumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Brolucizumab.
    Burosumab
    The risk or severity of adverse effects can be increased when Burosumab is combined with Eptinezumab.
    Canakinumab
    The risk or severity of adverse effects can be increased when Canakinumab is combined with Eptinezumab.
    Caplacizumab
    The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eptinezumab.
    Cemiplimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cemiplimab.
    Certolizumab pegol
    The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Eptinezumab.
    Cetuximab
    The risk or severity of adverse effects can be increased when Cetuximab is combined with Eptinezumab.
    Cilgavimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cilgavimab.
    Clesrovimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Clesrovimab.
    Conjugated estrogens
    Conjugated estrogens may increase the thrombogenic activities of Eptinezumab.
    Cosibelimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cosibelimab.
    Crovalimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Crovalimab.
    Daratumumab
    The risk or severity of adverse effects can be increased when Daratumumab is combined with Eptinezumab.
    Denosumab
    The risk or severity of adverse effects can be increased when Denosumab is combined with Eptinezumab.
    Digoxin Immune Fab (Ovine)
    The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eptinezumab.
    Dinutuximab
    The risk or severity of adverse effects can be increased when Dinutuximab is combined with Eptinezumab.
    Donanemab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Donanemab.
    Dostarlimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Dostarlimab.
    Dulaglutide
    The risk or severity of adverse effects can be increased when Dulaglutide is combined with Eptinezumab.
    Dupilumab
    The risk or severity of adverse effects can be increased when Dupilumab is combined with Eptinezumab.
    Durvalumab
    The risk or severity of adverse effects can be increased when Durvalumab is combined with Eptinezumab.
    Ebola Zaire vaccine (live, attenuated)
    The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Eptinezumab.
    Eculizumab
    The risk or severity of adverse effects can be increased when Eculizumab is combined with Eptinezumab.
    Eflapegrastim
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Eflapegrastim.
    Eftrenonacog alfa
    The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Eptinezumab.
    Elotuzumab
    The risk or severity of adverse effects can be increased when Elotuzumab is combined with Eptinezumab.
    Emapalumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Emapalumab.
    Emicizumab
    The risk or severity of adverse effects can be increased when Emicizumab is combined with Eptinezumab.
    Erenumab
    The risk or severity of adverse effects can be increased when Erenumab is combined with Eptinezumab.
    Esterified estrogens
    Esterified estrogens may increase the thrombogenic activities of Eptinezumab.
    Estetrol
    Estetrol may increase the thrombogenic activities of Eptinezumab.
    Estradiol
    Estradiol may increase the thrombogenic activities of Eptinezumab.
    Estradiol acetate
    Estradiol acetate may increase the thrombogenic activities of Eptinezumab.
    Estradiol cypionate
    Estradiol cypionate may increase the thrombogenic activities of Eptinezumab.
    Estradiol valerate
    Estradiol valerate may increase the thrombogenic activities of Eptinezumab.
    Estriol
    Estriol may increase the thrombogenic activities of Eptinezumab.
    Estrone sulfate
    Estrone sulfate may increase the thrombogenic activities of Eptinezumab.
    Ethinylestradiol
    Ethinylestradiol may increase the thrombogenic activities of Eptinezumab.
    Evolocumab
    The risk or severity of adverse effects can be increased when Evolocumab is combined with Eptinezumab.
    Fanolesomab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Fanolesomab.
    Fremanezumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Fremanezumab.
    Galcanezumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Galcanezumab.
    Gemtuzumab ozogamicin
    The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.
    Glofitamab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Glofitamab.
    Golimumab
    The risk or severity of adverse effects can be increased when Golimumab is combined with Eptinezumab.
    Guselkumab
    The risk or severity of adverse effects can be increased when Guselkumab is combined with Eptinezumab.
    Hepatitis B immune globulin
    The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Eptinezumab.
    Human cytomegalovirus immune globulin
    The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Eptinezumab.
    Human immunoglobulin G
    The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eptinezumab.
    Human Rho(D) immune globulin
    The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Eptinezumab.
    Human varicella-zoster immune globulin
    The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Eptinezumab.
    Ibalizumab
    The risk or severity of adverse effects can be increased when Ibalizumab is combined with Eptinezumab.
    Ibritumomab tiuxetan
    The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.
    Idarucizumab
    The risk or severity of adverse effects can be increased when Idarucizumab is combined with Eptinezumab.
    Inebilizumab
    The risk or severity of adverse effects can be increased when Inebilizumab is combined with Eptinezumab.
    Infliximab
    The risk or severity of adverse effects can be increased when Infliximab is combined with Eptinezumab.
    Inotuzumab ozogamicin
    The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eptinezumab.
    Ipilimumab
    The risk or severity of adverse effects can be increased when Ipilimumab is combined with Eptinezumab.
    Isatuximab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Isatuximab.
    Ixekizumab
    The risk or severity of adverse effects can be increased when Ixekizumab is combined with Eptinezumab.
    Lanadelumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Lanadelumab.
    Lebrikizumab
    The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Eptinezumab.
    Lecanemab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Lecanemab.
    Linvoseltamab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Linvoseltamab.
    Loncastuximab tesirine
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Loncastuximab tesirine.
    Maftivimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Maftivimab.
    Margetuximab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Margetuximab.
    Marstacimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Marstacimab.
    Mepolizumab
    The risk or severity of adverse effects can be increased when Mepolizumab is combined with Eptinezumab.
    Mirvetuximab soravtansine
    The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Eptinezumab.
    Mogamulizumab
    The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Eptinezumab.
    Mosunetuzumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Mosunetuzumab.
    Natalizumab
    The risk or severity of adverse effects can be increased when Natalizumab is combined with Eptinezumab.
    Necitumumab
    The risk or severity of adverse effects can be increased when Necitumumab is combined with Eptinezumab.
    Nemolizumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Nemolizumab.
    Nipocalimab
    The serum concentration of Eptinezumab can be decreased when it is combined with Nipocalimab.
    Nivolumab
    The risk or severity of adverse effects can be increased when Nivolumab is combined with Eptinezumab.
    Obiltoxaximab
    The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eptinezumab.
    Obinutuzumab
    The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Eptinezumab.
    Ocrelizumab
    The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Eptinezumab.
    Odesivimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Odesivimab.
    Ofatumumab
    The risk or severity of adverse effects can be increased when Ofatumumab is combined with Eptinezumab.
    Olaratumab
    The risk or severity of adverse effects can be increased when Olaratumab is combined with Eptinezumab.
    Omalizumab
    The risk or severity of adverse effects can be increased when Omalizumab is combined with Eptinezumab.
    Palivizumab
    The risk or severity of adverse effects can be increased when Palivizumab is combined with Eptinezumab.
    Panitumumab
    The risk or severity of adverse effects can be increased when Panitumumab is combined with Eptinezumab.
    Pembrolizumab
    The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Eptinezumab.
    Penpulimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Penpulimab.
    Pertuzumab
    The risk or severity of adverse effects can be increased when Pertuzumab is combined with Eptinezumab.
    Polatuzumab vedotin
    The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Eptinezumab.
    Ramucirumab
    The risk or severity of adverse effects can be increased when Ramucirumab is combined with Eptinezumab.
    Ranibizumab
    The risk or severity of adverse effects can be increased when Ranibizumab is combined with Eptinezumab.
    Ravulizumab
    The risk or severity of adverse effects can be increased when Ravulizumab is combined with Eptinezumab.
    Raxibacumab
    The risk or severity of adverse effects can be increased when Raxibacumab is combined with Eptinezumab.
    Relatlimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Relatlimab.
    Reslizumab
    The risk or severity of adverse effects can be increased when Reslizumab is combined with Eptinezumab.
    Risankizumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Risankizumab.
    Rituximab
    The risk or severity of adverse effects can be increased when Rituximab is combined with Eptinezumab.
    Romosozumab
    The risk or severity of adverse effects can be increased when Romosozumab is combined with Eptinezumab.
    Rozanolixizumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Rozanolixizumab.
    Sacituzumab govitecan
    The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Eptinezumab.
    Sarilumab
    The risk or severity of adverse effects can be increased when Sarilumab is combined with Eptinezumab.
    Secukinumab
    The risk or severity of adverse effects can be increased when Secukinumab is combined with Eptinezumab.
    Siltuximab
    The risk or severity of adverse effects can be increased when Siltuximab is combined with Eptinezumab.
    Sotatercept
    The risk or severity of adverse effects can be increased when Sotatercept is combined with Eptinezumab.
    Sotrovimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Sotrovimab.
    Spesolimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Spesolimab.
    Sutimlimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Sutimlimab.
    Synthetic Conjugated Estrogens, A
    Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Eptinezumab.
    Synthetic Conjugated Estrogens, B
    Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eptinezumab.
    Tafasitamab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tafasitamab.
    Telisotuzumab vedotin
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Telisotuzumab vedotin.
    Teplizumab
    The risk or severity of adverse effects can be increased when Teplizumab is combined with Eptinezumab.
    Teprotumumab
    The risk or severity of adverse effects can be increased when Teprotumumab is combined with Eptinezumab.
    Tetanus immune globulin, human
    The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Eptinezumab.
    Tezepelumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tezepelumab.
    Tildrakizumab
    The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Eptinezumab.
    Tislelizumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tislelizumab.
    Tisotumab vedotin
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tisotumab vedotin.
    Tixagevimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tixagevimab.
    Tocilizumab
    The risk or severity of adverse effects can be increased when Tocilizumab is combined with Eptinezumab.
    Toripalimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Toripalimab.
    Tralokinumab
    The risk or severity of adverse effects can be increased when Tralokinumab is combined with Eptinezumab.
    Trastuzumab
    The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eptinezumab.
    Trastuzumab deruxtecan
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Trastuzumab deruxtecan.
    Trastuzumab emtansine
    The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eptinezumab.
    Tremelimumab
    The risk or severity of adverse effects can be increased when Tremelimumab is combined with Eptinezumab.
    Ublituximab
    The risk or severity of adverse effects can be increased when Ublituximab is combined with Eptinezumab.
    Ustekinumab
    The risk or severity of adverse effects can be increased when Ustekinumab is combined with Eptinezumab.
    Vedolizumab
    The risk or severity of adverse effects can be increased when Vedolizumab is combined with Eptinezumab.
    Vilobelimab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Vilobelimab.
    Zanidatamab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Zanidatamab.
    Zenocutuzumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Zenocutuzumab.
    Zolbetuximab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Zolbetuximab.
    Coverage Restrictions for Get your patient on